Population Data-Driven Formulation of a COVID-19 Therapeutic.

HR Campbell; RP Cecil; R Lodder

doi:10.1101/2020.07.24.20161547

Population Data-Driven Formulation of a COVID-19 Therapeutic.

HR Campbell, RP Cecil, R Lodder

Research output: Contribution to journal › Article

Abstract

This study is designed to utilize computer modeling of the US population through NHANES to reduce the need for preclinical formulation and toxicology studies of an Ebola anti-viral (BSN389) being repurposed for COVID-19, and to thereby speed the candidate therapeutic to the clinic.

Original language	English
Journal	MedRxiv : the preprint server for health sciences
DOIs	https://doi.org/10.1101/2020.07.24.20161547
State	Published - Jul 27 2020

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1101/2020.07.24.20161547

Cite this

@article{80862127fad1490f8c24de849d80cf94,

title = "Population Data-Driven Formulation of a COVID-19 Therapeutic.",

abstract = "This study is designed to utilize computer modeling of the US population through NHANES to reduce the need for preclinical formulation and toxicology studies of an Ebola anti-viral (BSN389) being repurposed for COVID-19, and to thereby speed the candidate therapeutic to the clinic.",

author = "HR Campbell and RP Cecil and R Lodder",

year = "2020",

month = jul,

day = "27",

doi = "10.1101/2020.07.24.20161547",

language = "English",

}

TY - JOUR

T1 - Population Data-Driven Formulation of a COVID-19 Therapeutic.

AU - Campbell, HR

AU - Cecil, RP

AU - Lodder, R

PY - 2020/7/27

Y1 - 2020/7/27

N2 - This study is designed to utilize computer modeling of the US population through NHANES to reduce the need for preclinical formulation and toxicology studies of an Ebola anti-viral (BSN389) being repurposed for COVID-19, and to thereby speed the candidate therapeutic to the clinic.

AB - This study is designed to utilize computer modeling of the US population through NHANES to reduce the need for preclinical formulation and toxicology studies of an Ebola anti-viral (BSN389) being repurposed for COVID-19, and to thereby speed the candidate therapeutic to the clinic.

U2 - 10.1101/2020.07.24.20161547

DO - 10.1101/2020.07.24.20161547

M3 - Article

C2 - 32743601

JO - MedRxiv : the preprint server for health sciences

JF - MedRxiv : the preprint server for health sciences

ER -

Population Data-Driven Formulation of a COVID-19 Therapeutic.

Abstract

UN SDGs

Access to Document

Fingerprint

Cite this